Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuneering Corp Cl A (NQ: IMRX )

7.550 +0.070 (+0.94%)
Streaming Delayed Price Updated: 9:31 AM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 603
Open 7.380
Bid (Size) 7.370 (1)
Ask (Size) 7.790 (2)
Prev. Close 7.480
Today's Range 7.380 - 7.550
52wk Range 3.700 - 16.17
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immuneering to Present at the Morgan Stanley Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
4 Analysts Have This to Say About Immuneering
Via Benzinga

Performance

YTD
+88.28%
+88.28%
1 Month
-17.21%
-17.21%
3 Month
-20.27%
-20.27%
6 Month
-25.47%
-25.47%
1 Year
-28.71%
-28.71%

More News

Read More
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Expert Ratings for Immuneering
Via Benzinga
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Analyst Doubles Immuneering Price Target Citing Initial Data Validation
Via Benzinga
What 7 Analyst Ratings Have To Say About Immuneering
Via Benzinga
Immuneering to Present at the Jefferies Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces $30 Million Underwritten Offering
From Immuneering Corporation
Via GlobeNewswire
Why Shares of Immuneering Jumped This Week
Via The Motley Fool
Looking Into Immuneering's Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
Via Benzinga
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via GlobeNewswire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
From Immuneering Corporation
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.